Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010
Vaccine, ISSN: 0264-410X, Vol: 31, Issue: 14, Page: 1819-1829
2013
- 55Citations
- 134Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations55
- Citation Indexes52
- 52
- CrossRef42
- Policy Citations3
- Policy Citation3
- Captures134
- Readers134
- 134
- Mentions1
- News Mentions1
- News1
Most Recent News
Adverse Events Following a Mass Yellow Fever Immunization Campaign - Kongo Central Province, Democratic Republic of the Congo, September 2016
FULL TEXT On April 23, 2016, the Democratic Republic of the Congo (DRC) Ministry of Health reported an outbreak of yellow fever. As of May
Article Description
Serious, but rare adverse events following immunization (AEFI) have been reported with yellow fever (YF) 17D vaccine, including severe allergic reactions, YF vaccine-associated neurologic disease (YEL-AND) and YF vaccine-associated viscerotropic disease (YEL-AVD). The frequency with which YEL-AND and YEL-AVD occur in YF endemic countries is mostly unknown. From 2007 to 2010, eight African countries – Benin, Cameroon, Guinea, Liberia, Mali, Senegal, Sierra Leone, and Togo- implemented large-scale YF preventive vaccination campaigns. Each country established vaccine pharmacovigilance systems that included standard case definitions, procedures to collect and transport biological specimens, and National Expert Committees to review data and classify cases. Staff in all countries received training and laboratory capacity expanded. In total, just over 38 million people were vaccinated against YF and 3116 AEFIs were reported of which 164 (5%) were classified as serious. Of these, 22 (13%) were classified as YF vaccine reactions, including 11 (50%) hypersensitivity reactions, six (27%) suspected YEL-AND, and five (23%) suspected YEL-AVD. The incidence per 100,000 vaccine doses administered was 8.2 for all reported AEFIs, 0.43 for any serious AEFI, 0.058 for YF vaccine related AEFIs, 0.029 for hypersensitivity reactions, 0.016 for YEL-AND, and 0.013 for YEL-AVD. Our findings were limited by operational challenges, including difficulties in obtaining recommended biological specimens leading to incomplete laboratory evaluation, unknown case ascertainment, and variable levels of staff training and experience. Despite limitations, active case-finding in the eight different countries did not find an incidence of YF vaccine associated AEFIs that was higher than previous reports. These data reinforce the safety profile of YF vaccine and support the continued use of attenuated YF vaccine during preventive mass vaccination campaigns in YF endemic areas.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X13001321; http://dx.doi.org/10.1016/j.vaccine.2013.01.054; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84875266874&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23395587; https://linkinghub.elsevier.com/retrieve/pii/S0264410X13001321; https://dx.doi.org/10.1016/j.vaccine.2013.01.054
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know